You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Bevacizumab

Showing 1 - 25 of 2,998
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal

Completed
Has Results
  • Platinum-Resistant Fallopian Tube Carcinoma
  • +8 more
  • Bevacizumab
  • Irinotecan Sucrosofate
  • Chicago, Illinois
    Northwestern University
Dec 21, 2022

Resectable Hepatocellular Carcinoma, Stage I Hepatocellular Carcinoma AJCC v8, Stage IA Hepatocellular Carcinoma AJCC v8 Trial

Recruiting
  • Resectable Hepatocellular Carcinoma
  • +4 more
  • Atezolizumab
  • +2 more
  • Houston, Texas
  • +1 more
Oct 12, 2022

89Zr-Bevacizumab PET/CT Imaging in NF2 Patients

Recruiting
  • Neurofibromatosis 2
  • Bevacizumab Zirconium Zr-89
  • Leiden, Zuid-Holland, Netherlands
    Leiden University Medical Center
Jan 5, 2023

Ovarian Clear Cell Adenocarcinoma, Platinum-Sensitive Ovarian Carcinoma, Recurrent Endometrial Serous Adenocarcinoma Trial in

Not yet recruiting
  • Ovarian Clear Cell Adenocarcinoma
  • +14 more
  • Anti-CD40 Agonist Monoclonal Antibody CDX-1140
  • +4 more
  • Buffalo, New York
  • +1 more
Dec 16, 2022

Fallopian Tube Carcinosarcoma, Fallopian Tube Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma Trial in Buffalo

Not yet recruiting
  • Fallopian Tube Carcinosarcoma
  • +10 more
  • Bevacizumab
  • +4 more
  • Buffalo, New York
    Roswell Park Cancer Institute
Dec 29, 2022

Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Tumor in the Brain, Stage IV Lung Non-Small Cell Cancer AJCC v7

Active, not recruiting
  • Metastatic Lung Non-Small Cell Carcinoma
  • +2 more
  • Bevacizumab
  • +2 more
  • Los Angeles, California
  • +17 more
Jan 27, 2023

Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IIIC Lung Cancer AJCC v8 Trial in

Recruiting
  • Metastatic Lung Non-Small Cell Carcinoma
  • +5 more
  • Bevacizumab
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
Jul 13, 2022

Metastatic Colorectal Cancer Trial in Guangzhou (Fruquintinib alternating with Bevacizumab plus Capecitabine, Bevacizumab plus

Recruiting
  • Metastatic Colorectal Cancer
  • Fruquintinib alternating with Bevacizumab plus Capecitabine
  • Bevacizumab plus Capecitabine
  • Guangzhou, Guangdong, China
    Nanfang Hospital, Southern Medical University
Jan 4, 2023

Hepatocellular Carcinoma Trial in Guangzhou (Candonilimab, Bevacizumab)

Withdrawn
  • Hepatocellular Carcinoma
  • Guangzhou, Guangdong, China
    Cancer Center Sun Yat-sen University
Jun 1, 2023

Hepatocellular Carcinoma Trial in Guangzhou (Candonilimab, Bevacizumab)

Recruiting
  • Hepatocellular Carcinoma
  • Guangzhou, Guangdong, China
    Cancer Center Sun Yat-sen University
Feb 26, 2023

Recurrent Glioblastoma Trial in Zhengzhou (Tislelizumab plus Bevacizumab)

Recruiting
  • Recurrent Glioblastoma
  • Tislelizumab plus Bevacizumab
  • Zhengzhou, Henan, China
    Henan Provincial People's Hospital
Sep 11, 2022

Cervical Adenocarcinoma, Cervical Adenosarcoma, Cervical Adenosquamous Carcinoma Trial in United States (biological, other,

Recruiting
  • Cervical Adenocarcinoma
  • +47 more
  • Bevacizumab
  • +3 more
  • Phoenix, Arizona
  • +3 more
Dec 5, 2022

Locally Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell

Recruiting
  • Locally Advanced Lung Non-Small Cell Carcinoma
  • +9 more
  • Duarte, California
  • +4 more
Aug 17, 2022

Colorectal Cancer Metastatic Trial in Guangzhou (Dexamethasone, Anisodamine, Oxaliplatin)

Recruiting
  • Colorectal Cancer Metastatic
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Feb 3, 2023

Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma

Active, not recruiting
  • Fallopian Tube Endometrioid Adenocarcinoma
  • +7 more
  • Anetumab Ravtansine
  • +2 more
  • Orange, California
  • +22 more
Oct 22, 2022

Colorectal Cancer Trial in Guangzhou (mFOLFOXIRI plus Bevacizumab, mFOLFOX6 Plus Bevacizumab)

Recruiting
  • Colorectal Cancer
  • mFOLFOXIRI plus Bevacizumab
  • mFOLFOX6 Plus Bevacizumab
  • Guangzhou, Guangdong, China
    Gastrointestinal Hospital, Sun Yat-sen University
Jun 15, 2022

Colorectal Cancer Trial (ME-344, Bevacizumab)

Not yet recruiting
  • Colorectal Cancer
  • (no location specified)
Apr 20, 2023

Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer Trial (Mirvetuximab soravtansine plus Bevacizumab, Bevacizumab)

Recruiting
  • Ovarian Cancer
  • +2 more
  • Mirvetuximab soravtansine plus Bevacizumab
  • Bevacizumab
  • New Orleans, Louisiana
  • +3 more
Dec 16, 2022

Invasive Breast Carcinoma, Triple-Negative Breast Carcinoma Trial in Houston (biological, drug, other)

Active, not recruiting
  • Invasive Breast Carcinoma
  • Triple-Negative Breast Carcinoma
  • Bevacizumab
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
Feb 18, 2022

Recurrent, or Metastatic Cervical Cancer With PD-L1 Positive (CPS=1) Trial (SG001 injection, Paclitaxel, Cisplatin)

Not yet recruiting
  • Recurrent, or Metastatic Cervical Cancer With PD-L1 Positive (CPS≥1)
  • SG001 injection
  • +5 more
  • (no location specified)
Jan 27, 2023

Glioblastoma Trial in Boston, New York, Philadelphia (Pembrolizumab, Bevacizumab, Re-irradiation)

Active, not recruiting
  • Glioblastoma
  • Boston, Massachusetts
  • +4 more
Dec 7, 2022

Metastatic Colon Adenocarcinoma, Metastatic Colorectal Adenocarcinoma, Metastatic Microsatellite Stable Colorectal Carcinoma

Not yet recruiting
  • Metastatic Colon Adenocarcinoma
  • +6 more
  • Balstilimab
  • +10 more
  • Duarte, California
    City of Hope Medical Center
Nov 17, 2022

Glioblastoma Multiforme, Anaplastic Astrocytoma Trial in New York (Bevacizumab)

Recruiting
  • Glioblastoma Multiforme
  • Anaplastic Astrocytoma
  • Bevacizumab
  • New York, New York
    Lenox Hill Brain Tumor Center
Nov 10, 2022

Recurrent Glioblastoma Trial (Sintilimab plus Bevacizumab and Temozolomide)

Not yet recruiting
  • Recurrent Glioblastoma
  • Sintilimab plus Bevacizumab and Temozolomide
  • (no location specified)
Nov 27, 2022

Glioma Trial in Madison (Bevacizumab, PRDR)

Recruiting
  • Glioma
  • Bevacizumab
  • PRDR
  • Madison, Wisconsin
    University of Wisconsin Hospital and Clinics
Nov 14, 2022